Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of ...

Researchers in Gastroenterology evaluated strategies for preventing avoidable colorectal cancers after colonoscopy. In ...

Its efficacy and safety have not been established. AGMB-129 is an oral, small molecule GI-restricted inhibitor of ALK5 (or TGF-β RI) currently in clinical development for the treatment of ...

Belgian biotech Agomab Therapeutics (Nasdaq: AGMB) has reported positive interim results from its Phase IIa STENOVA trial of ...

Agomab Therapeutics NV (Agomab) has announced positive interim results from 44 patients completing treatment in the ongoing ...

Belgium-based Agomab will use some of the proceeds to fund a recently-started phase 2 trial of its lead ALK5 inhibitor AGMB-129 for fibrostenosing Crohn’s disease, a severe form that often ...

Agomab Therapeutics NV (‘Agomab’) today announced positive interim results from 44 patients completing treatment in the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal ...

AGMB-129 hit all primary and secondary endpoints in interim read-out from 44 patients after 12 weeks treatment -- -- Detailed interim STENOVA results to be presented at future scientific conference ...